comprehensive -WSS

comprehensive

author：Wikipedia 2025-08-03 10:43:05 - browse：5137

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： FDA weighs limits of animal data in assessing artificial wombs

focus

WSS

People with substance use disorder deserve online privacy

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

How the messy conversation about Dolly changed bioethics

People with substance use disorder deserve online privacy

Will an HIV vaccine ever be a reality?

Why the drug industry's warnings on the IRA's impact fall short

hotspot

comprehensive

focus

Alkermes shareholders re

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Medical leaders decry Supreme Court decision on affirmative action

Akili changes sales model for its ADHD video game treatment

Guidelines to prevent youth baseball injuries need more muscle

PBMs drew scrutiny in House hearing — and so did pharma

Malaria cases in Florida and Texas: Here’s what you need to know

Neurocrine congenital adrenal hyperplasia trial succeeds

Novavax promises a turnaround & Lilly roils the obesity market

People with substance use disorder deserve online privacy

focus

Medicare innovation center doesn’t save money, experts say

Akili changes sales model for its ADHD video game treatment

European officials brace for rough respiratory virus season

RSV injection headlines need to be accurate for good uptake

White House Covid adviser calls on docs to combat misinformation

Information blocking fines are now fair game in health care

hotspot

hotspot

focus

leisure time